Expression of Functional Prostaglandin D (DP) Receptors in Human Corpus Cavernosum Smooth Muscle

Total Page:16

File Type:pdf, Size:1020Kb

Expression of Functional Prostaglandin D (DP) Receptors in Human Corpus Cavernosum Smooth Muscle International Journal of Impotence Research (2002) 14, 446–452 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Expression of functional prostaglandin D (DP) receptors in human corpus cavernosum smooth muscle RB Moreland1*, A Nehra2,NNKim1, Kweon-sik Min1, H Albadawi3,4, MT Watkins3,4, I Goldstein1 and AM Traish1,5 1Department of Urology, Boston University School of Medicine, Boston, Massachusetts, USA; 2Department of Urology, Mayo Clinic and Foundation, Rochester, Minnesota, USA; 3Department of Surgery, Boston University School of Medicine, Boston, Massachusetts, USA; 4Department of Pathology, Boston University School of Medicine, Boston, Massachusetts, USA; and 5Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, USA Prostaglandin D2 (PGD2) binds to specific G-protein coupled receptors (DP) and induces smooth muscle relaxation by stimulating the synthesis of intracellular cAMP. In this study, we examined the role of PGD2 and DP receptors in regulating human penile smooth muscle contractility. We determined that human corpus cavernosum tissue and smooth muscle cells in culture expressed functional DP receptor and lipocalin-like prostaglandin D synthase by reverse-transcribed polymerase chain reaction (RT-PCR). Functional PGD synthase activity was confirmed by the synthesis of PGD2 in human corpus cavernosum smooth muscle cells upon addition of exogenous arachidonic acid. Organ bath preparations of human corpus cavernosum tissue strips, contracted with phenylephrine, relaxed in a dose-dependent fashion to either PGD2 or the DP selective agonist BW245C. Cultures of human corpus cavernosum smooth muscle cells treated with BW245C showed a two-fold increase in cAMP synthesis. These data are consistent with the expression of functional DP receptors in human corpus cavernosum. This suggests the presence of an intact prostanoid autocrine system that may play a role in regulating penile erectile function. International Journal of Impotence Research (2002) 14, 446–452. doi:10.1038=sj.ijir.3900900 Keywords: DP receptor; PGD2; vascular smooth muscle; lipocalin PGD synthase; corpus cavernosum; erectile dysfunction Introduction smooth muscle is a major determinant of blood flow within the erectile tissue and regulates tume- scence.3,4 In addition to their vasoactive properties, Prostanoids are bioactive lipids derived from prostanoids play key roles in regulating diverse 20-carbon, polyunsaturated fatty acids. The physiological processes. Prostaglandin D modu- 1,2 2 most common precursor is arachidonic acid. lates nociception, body temperature, olfactory func- Prostaglandin G=H synthase (cox 1 and cox 2) tion, sleep, immune response and hormone release converts arachidonic acid to prostaglandin H2, in the central nervous system and in the peri- requiring oxygen as a co-substrate. Prostaglandin phery.2,5 – 7 The DP receptor, which binds PGD, is the H2 is then converted to PGD2, PGE2, PGF2a, PGI2 least characterized with respect to expression and (prostacyclin) and TxA2 (thromboxane A2) by dis- biochemical and physiological properties, relative to tinct synthases. These prostanoids interact with other prostanoid receptors.2,5 Detectable expression specific G-protein-coupled receptors and, depend- of human DP receptor mRNA has been reported only ing on the prostanoid and receptor subtype, mediate in the retina and small intestine.2,5 Cells transfected 1,2 smooth muscle relaxation or contraction. In the with the cloned human DP receptor cDNA or freshly penis, the contractile state of corpus cavernosum isolated nonchromaffin cells from bovine adrenal medulla respond to prostaglandin D2 and other DP agonists with increased cAMP synthesis and calcium *Correspondence: RB Moreland, PhD, Neuroscience mobilization.5,8 Research, Global Pharmaceutical Research and Development, Building AP9, Room 1125, Abbott Laboratories, 100 Abbott Prostaglandin D2 is synthesized from PGH2 by Park Road, Abbott Park, IL 60064-6118, USA. glutathione-independent, lipocalin PGD synthase E-mail: [email protected] or glutathione-dependent, hematopoietic PGD Received 11 January 2002; revised 4 April 2002; synthase; both of which have been cloned.6,9 The accepted 26 April 2002 synthesis of PGE2, PGF2a, PGI2 and TxA2 by human Functional DP receptors in trabecular smooth muscle RB Moreland et al 447 penile corpus cavernosum and the effects of these amplified products were 484 bp for DP receptor and prostanoids on human corpus cavernosum tissue 370 bp for lipocalin PGD synthase. Digestion at and smooth muscle cells have been previously unique restriction endonuclease sites within the 3,10 – 15 reported. However, the synthesis of PGD2 amplified fragments (ScaI for DP receptor, XhoI for and the expression of functional DP receptors in PGD synthase) was utilized to further confirm the human corpus cavernosum smooth muscle are yet identity of the DNA products. cDNA for DP receptor to be determined. The goal of this study was to and PGD synthase were cloned by RT-PCR using the investigate the synthesis of PGD2 in human corpus same primer sets and Pfx-Platinum thermostable cavernosum and the ability of PGD2 to elicit polymerase (Life Sciences, Bethesda, MD), a faithful, biological response in this tissue. proof reading polymerase. Reaction conditions included human corpus cavernosum or small intes- tine cDNA and amplification at 94C, 65C, 68C for Materials and methods PGD synthase and 94 C, 72 C, 68 C for the DP receptor. Blunt-ended DNA fragments were isolated Chemicals and supplies and cloned into pCR-Script AMP (Stratagene, La Jolla, CA) and DNA sequenced at our institutional core facility. BW245C, PGD1, PGD2 and SQ29,548 were obtained from Cayman Chemical Company (Ann Arbor, MI). ELISA kits for PGD assay were obtained from R&D PGD2 synthesis by human corpus cavernosum Systems (Minneapolis, MN) while cAMP radio- smooth muscle cells immunoassay kits were obtained from Biomedical Technologies (Stoughton, MA). Pfx Platinum poly- merase, Taq DNA polymerase and Superscript II Human corpus cavernosum smooth muscle cells Moloney virus reverse transcriptase were obtained were grown from tissue explants17 and cultured from Life Sciences (Rockville, MD). All other on CytodexTM III microcarrier beads (Pharmacia, restriction endonucleases and molecular biological Piscataway, NJ), as previously described for human supplies were obtained from New England Biolabs corpus cavernosum smooth muscle cells12 and (Beverly, MA), unless noted. All chemicals were of human umbilical endothelial cells.19 Cells were reagent grade. grown and maintained under low shear conditions at media PO2 corresponding to blood PO2 during penile erection (100 mm Hg).20 Cells were incubated RT-PCR assay for DP receptor expression with exogenous 20 mM arachidonate for 30 min. Media was collected, treated with methyloxime to prevent decay of PGD2, clarified by centrifugation at Primers for RT-PCR were designed such that they 1000 g for 1 min, frozen in liquid nitrogen and stored flanked one or more exon – intron junctions and were at 770C until assay. A commercially available as follows: human DP receptor 50-CAGAACCGGAG- ELISA kit (Cayman Chemicals, Ann Arbor, MI) was 0 TCTGCGG (nucleotides 614 – 635), 3 -GGGACGCT- used to assess PGD2 production. This protocol was TCCCTCCCGTCC (nucleotides 1092 – 1113)5 and repeated four times, using cells from four different human lipocalin PGD synthase 50-CACACCACTGG- patients. CACCAGGCCC (nucleotides 40 – 79), 30-CCGGT AGCTGTAGGAGCCGAG (nucleotides 382 – 430).9 Total RNA from human kidney and small intestine Organ baths was purchased from Clontech (Palo Alto, CA). Total RNA from human Jurkatt cells and from IMR90 human neonatal lung fibroblasts were the gifts from The Institutional Review Boards at Boston Drs Douglas Faller and Peter Polgar, respectively University Medical Center and the Mayo Clinic (Boston University School of Medicine, Boston, MA). and Foundation approved the use of human tissue. Total RNA was prepared from human corpus caver- Human corpus cavernosum tissue was obtained nosum biopsies and cultured human corpus caverno- during penile prosthesis insertion. Patients ranged sum smooth muscle cells as previously reported.17 from 45 to 70 y of age and had a variety of etiologies Reverse transcription was carried out as previously including radical prostatectomy, pelvic trauma, described18 using random hexamers (Perkin Elmer- peripheral vascular disease, diabetes mellitus and Cetus, Foster City, CA) and Superscript II Moloney Peyronie’s disease. Organ bath experiments were virus reverse transcriptase (Life Sciences, Bethesda, carried out as previously reported.15,16 Human MD). Polymerase chain reaction (PCR) was carried corpus cavernosum tissue strips at optimal iso- out using 40 cycles of 1 min each at 94C, 65C, 72C metric tension were contracted with 1 mM phenyl- in an MJ Research Model 200 thermocycler (MJ ephrine. After stable contraction was attained, Research, Watertown, MA). Expected sizes of the tissue strips were exposed to increasing concentra- International Journal of Impotence Research Functional DP receptors in trabecular smooth muscle RB Moreland et al 448 711 76 tions of BW245C (10 – 10 M), PGD1 or PGD2 treated with increasing concentrations of BW245C (10710 – 1075 M). In some experiments, tissue strips (10711 – 1076 M) for 5 min. The incubations were were incubated with the TxA2 receptor antagonist terminated by quickly aspirating the medium and 15 SQ29,548 (10 mM) before exposure
Recommended publications
  • Estimation of Serum Prostaglandin D2 Levels and Its Expression in Tissue of Alopecia Areata
    ISSN: 2536-9474 (Print) Original article / FYMJ ISSN: 2536-9482 (Online) Fayoum University Medical Journal Soliman et al., 2019,4(1), 77-85 Estimation of serum prostaglandin D2 levels and its expression in tissue of Alopecia areata Talal A. Abd-ElRaheem1, Samar M.R. El-Tahlawy2, Olfat G. Shaker3, Mohamed H.Mohamed4 and Yasmin F.Soliman5 1. M.D, professor of Dermatology, STDs and Andrology department, Faculty of Medicine Fayoum University. 2. M.D, professor of Dermatology department, Faculty of Medicine Cairo University 3. M.D, professor of Biochemistry department, Faculty of Medicine-Cairo University 4. MD, lecturer of Dermatology, STDs and Andrology department, Faculty of Medicine Fayoum University 5. M.B.B.CH, Dermatology, STDs and Andrology department, Faculty of Medicine, Cairo University Abstract Results: There was statistically highly Back ground: Alopecia areata is a recurrent, significant difference between the two groups non-scaring type of hair loss considered to be regarding the mean value of PGD2 in tissue in an autoimmune process. Though its AA patients. It was significantly lower than in etiopathogenesis is not fully understood, many control group (p < 0.001). The mean value of therapeutic options have been used by PGD2 in serum in AA patients was dermatologists, but none are curative or significantly lower than in control group (p< preventive. Prostaglandins analogues which 0.05). are used to treat glaucoma. Increase in eye lash Conclusion: Prostaglandin D2 exhibits a number, thickness and pigmentation have been strong role in etiology of alopecia areata and reported as side effect. significantly was elevated in serum and tissue Methods: This cross sectional case control of alopecia areata patients.
    [Show full text]
  • New Investigational Drugs for Androgenetic Alopecia. Valente Duarte De Sousa IC 1, Tosti A
    Expert Opin Investig Drugs. 2013 May;22(5):573-89. doi: 10.1517/13543784.2013.784743. Epub 2013 Apr 4. New investigational drugs for androgenetic alopecia. Valente Duarte de Sousa IC 1, Tosti A . Author information • [email protected] Erratum in • Erratum. [Expert Opin Investig Drugs. 2015] Abstract INTRODUCTION: Androgenetic alopecia (AGA) is the most common form of hair loss, however current treatment options are limited and moderately effective. In the past few years, there has been an increased interest in deciphering the molecular mechanisms responsible for this disorder, which has opened the possibility of novel treatments that promise to not only stimulate hair growth, but also to induce formation of new hair follicles. AREAS COVERED: The future holds more effective topical treatments with less systemic side effects (such as topical 5- alfa-reductase inhibitors), prostaglandin analogs and antagonists, medications which act through the Wnt signaling pathway, stem cells for hair regeneration, platelet-rich plasma (PRP) and more effective ways of transplanting hair. A comprehensive search was made using PubMed, GoogleScholar and Clinicaltrial.gov using different combination of key words, which included AGA treatment, new treatments for AGA, Wnt pathway, prostaglandins, PRP and stem cells for hair regrowth. EXPERT OPINION: In the near future, treatments with topical 5-alfa-reductase inhibitors and prostaglandin agonists or antagonists are expected. More evidence is needed to verify the efficacy of PRP. Although hair follicle bioengineering and multiplication is a fascinating and promising field, it is still a long way from being available to clinicians. J Am Acad Dermatol. 2015 Apr;72(4):712-6.
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Prostaglandin D2, a Neuromodulator
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 12, pp. 6231-6234, December 1979 Biochemistry Prostaglandin D2, a neuromodulator (prostaglandin D synthetase/enzyme distribution/neuroblastoma cell/cyclic AMP) TAKAO SHIMIZU, NOBORU MIZUNO*, TAKEHIKO AMANOt, AND OSAMU HAYAISHI Department of Medical Chemistry, and *Department of Anatomy, Kyoto University Faculty of Medicine, Sakyo-ku, Kyoto 606, Japan; and tMitsubishi-Kasei Institute of Life Sciences, Machida-shi, Tokyo 194, Japan Contributed by Osamu Hayaishi, September 17, 1979 ABSTRACT The distribution of prostaglandin D synthetase were quickly removed. The brain was chilled on ice and sepa- activity was determined in various tissues of rat by using the rated into 11 parts-cerebral neocortex, cerebellum, pons and supernatant fraction (10,000 X g, 20 min) of the homogenates. medulla oblongata, midbrain, hypothalamus, thalamus, bulbus The highest activity was found in brain, spinal cord, and ali- and mentary tract. The activity was ubiquitously distributed in all olfactorius, hippocampus, caudoputamen, pineal body, parts of brain, and the highest specific activity was found in meninges. These tissues were weighed and homogenized with hypothalamus and thalamus. Homogenates of two neuroblas- 2 vol of 10 mM potassium phosphate buffer (pH 6.0) containing toma cell lines were found to produce prostaglandin D2, 0.5 mM dithiothreitol in a Polytron homogenizer. Mouse neu- whereas a glioma cell line was almost inactive. Prostaglandin roblastoma cells (NS-20 and N1E-115) and rat glioma cells (C6 D2 is a potent and specific activator of the adenylate cyclase BU-1) (see below) were sonicated with a Branson Sonifier model system of cultured neuroblastoma cells, suggesting the possi- were bility that it may act as a neuromodulator in the central nervous W 185D (output 4, for 1.5 min).
    [Show full text]
  • Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis Through the Receptor, Gpr44 Amanda M
    ORIGINAL ARTICLE Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis through the Receptor, Gpr44 Amanda M. Nelson1,5, Dorothy E. Loy2,5, John A. Lawson3,4, Adiya S. Katseff1, Garret A. FitzGerald3,4 and Luis A. Garza1 Prostaglandins (PGs) are key inflammatory mediators involved in wound healing and regulating hair growth; however, their role in skin regeneration after injury is unknown. Using wound-induced hair follicle neogenesis (WIHN) as a marker of skin regeneration, we hypothesized that PGD2 decreases follicle neogenesis. PGE2 and PGD2 were elevated early and late, respectively, during wound healing. The levels of WIHN, lipocalin-type prostaglandin D2 synthase (Ptgds), and its product PGD2 each varied significantly among background strains of mice after wounding, and all correlated such that the highest Ptgds and PGD2 levels were associated with the lowest amount of regeneration. In addition, an alternatively spliced transcript variant of Ptgds missing exon 3 correlated with high regeneration in mice. Exogenous application of PGD2 decreased WIHN in wild-type mice, and PGD2 receptor Gpr44-null mice showed increased WIHN compared with strain-matched control mice. Furthermore, Gpr44-null mice were resistant to PGD2-induced inhibition of follicle neogenesis. In all, these findings demonstrate that PGD2 inhibits hair follicle regeneration through the Gpr44 receptor and imply that inhibition of PGD2 production or Gpr44 signaling will promote skin regeneration. Journal of Investigative Dermatology (2013) 133, 881–889; doi:10.1038/jid.2012.398; published online 29 November 2012 INTRODUCTION successfully transition through all phases of the hair cycle, Scar formation and tissue regeneration are opposite results of and include associated structures, such as sebaceous glands the wound healing process.
    [Show full text]
  • Prostaglandin D2 Acts Through the Dp2 Receptor to Influence Male Germ Cell Differentiation in the Foetal Mouse Testis
    © 2014. Published by The Company of Biologists Ltd | Development (2014) 141, 3561-3571 doi:10.1242/dev.103408 RESEARCH ARTICLE Prostaglandin D2 acts through the Dp2 receptor to influence male germ cell differentiation in the foetal mouse testis Brigitte Moniot1, Safdar Ujjan1, Julien Champagne1, Hiroyuki Hirai2, Kosuke Aritake3, Kinya Nagata2, Emeric Dubois4, Sabine Nidelet4, Masataka Nakamura5, Yoshihiro Urade3, Francis Poulat1,* and Brigitte Boizet-Bonhoure1,* ABSTRACT sexual fate of the germ cells becomes apparent between E12.5 and Through intercellular signalling, the somatic compartment of the E15.5. In the developing ovary, germ cells stop undergoing foetal testis is able to program primordial germ cells to undergo mitosis and enter the prophase of the first meiotic division at spermatogenesis. Fibroblast growth factor 9 and several members of E13.5. In the testicular environment, the proliferation of germ β cells gradually slows down and the cells ultimately reach the transforming growth factor superfamily are involved in this ‘ ’ process in the foetal testis, counteracting the induction of meiosis by quiescence, also called mitotic arrest , which corresponds to a retinoic acid and activating germinal mitotic arrest. Here, using block in the G0/G1 phase. Male germ cells remain quiescent until in vitro and in vivo approaches, we show that prostaglandin D shortly after birth, at which time they resume mitosis and then 2 initiate meiosis at around 8 dpp (days post partum) (for a review, (PGD2), which is produced through both L-Pgds and H-Pgds enzymatic activities in the somatic and germ cell compartments of see Ewen and Koopman, 2010). the foetal testis, plays a role in mitotic arrest in male germ cells by This male-specific quiescence is a crucial event in the activating the expression and nuclear localization of the CDK establishment of the male germ cell fate and is tightly associated inhibitor p21Cip1 and by repressing pluripotency markers.
    [Show full text]
  • The EP2 Receptor Is the Predominant Prostanoid Receptor in the Human
    110 BritishJournalofOphthalmology 1993; 77: 110-114 The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle Br J Ophthalmol: first published as 10.1136/bjo.77.2.110 on 1 February 1993. Downloaded from Toshihiko Matsuo, Max S Cynader Abstract IP prostanoid receptors, respectively. The EP Prostaglandins canreduce intraocularpressure receptor can be further classified into three by increasing uveoscleral outflow. We have subtypes, called EPI, EP2, and EP3 previously demonstrated that the human receptors.'89 The framework of the receptor ciliary muscle was a zone of concentration for classification has been supported in part, by binding sites (receptors) for prostaglandin F2a cloning and expression of cDNA for a human and for prostaglandin E2. Here, we try to thromboxane A2 receptor.20 elucidate the types of prostanoid receptors in It is important to know the types ofprostanoid the ciliary muscle using competitive ligand receptors located on the human ciliary muscle in binding studies in human eye sections and order to understand its role in uveoscleral out- computer assisted autoradiographic densito- flow, and to design new drugs with more potency metry. Saturation binding curves showed that and fewer adverse effects. In this study we tried the human ciliary muscle had a large number of to elucidate the type(s) of prostanoid receptors binding sites with a high affinity for prosta- located on the human ciliary muscle by glandin E2 compared with prostaglandin D2 combining receptor autoradiography with and F2,. The binding oftritiated prostaglandin competitive binding studies with various ligands E2 and F2a in the ciliary muscle was displaced on human eye sections.
    [Show full text]
  • The Prostaglandin Receptor EP2 Determines Prognosis in EP3
    www.nature.com/scientificreports OPEN The prostaglandin receptor EP2 determines prognosis in EP3- negative and galectin-3-high cervical cancer cases Sebastian Dietlmeier1, Yao Ye1, Christina Kuhn1, Aurelia Vattai1, Theresa Vilsmaier1, Lennard Schröder1, Bernd P. Kost1, Julia Gallwas1, Udo Jeschke 1,2*, Sven Mahner1,2 & Helene Hildegard Heidegger1 Recently our study identifed EP3 receptor and galectin-3 as prognosticators of cervical cancer. The aim of the present study was the analysis of EP2 as a novel marker and its association to EP3, galectin-3, clinical pathological parameters and the overall survival rate of cervical cancer patients. Cervical cancer tissues (n = 250), as also used in our previous study, were stained with anti-EP2 antibodies employing a standardized immunohistochemistry protocol. Staining results were analyzed by the IRS scores and evaluated for its association with clinical-pathological parameters. H-test of EP2 percent-score showed signifcantly diferent expression in FIGO I-IV stages and tumor stages. Kaplan-Meier survival analyses indicated that EP3-negative/EP2-high staining patients (EP2 IRS score ≥2) had a signifcantly higher survival rate than the EP3-negative/EP2-low staining cases (p = 0.049). In the subgroup of high galectin-3 expressing patients, the group with high EP2 levels (IRS ≥2) had signifcantly better survival rates compared to EP2-low expressing group (IRS <2, p = 0.044). We demonstrated that the EP2 receptor is a prognostic factor for the overall survival in the subgroup of negative EP3 and high galectin-3 expressed cervical cancer patients. EP2 in combination with EP3 or galectin-3 might act as prognostic indicators of cervical cancer.
    [Show full text]
  • Binding and Activity of the Prostacyclin Receptor (IP) Agonists, Treprostinil
    Biochemical Pharmacology 84 (2012) 68–75 Contents lists available at SciVerse ScienceDirect Biochemical Pharmacology jo urnal homepage: www.elsevier.com/locate/biochempharm Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist a b b c, Brendan J. Whittle , Adam M. Silverstein , David M. Mottola , Lucie H. Clapp * a William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK b United Therapeutics Corporation, 55 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA c Centre for Clinical Pharmacology, Division of Medicine, University College London, Rayne Building, London WC1E 6JF, UK A R T I C L E I N F O A B S T R A C T Article history: The prostacyclin analogues, iloprost and treprostinil are extensively used in treating pulmonary Received 24 January 2012 hypertension. Their binding profile and corresponding biochemical cellular responses on human prostanoid Accepted 19 March 2012 receptors expressed in cell lines, have now been compared. Iloprost had high binding affinity for EP1 and IP Available online 27 March 2012 receptors (Ki 1.1 and 3.9 nM, respectively), low affinity for FP, EP3 or EP4 receptors, and very low affinity for EP2, DP1 or TP receptors. By contrast, treprostinil had high affinity for the DP1, EP2 and IP receptors (Ki 4.4, 3.6 Keywords: and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP Prostacyclin analogues receptors.
    [Show full text]
  • Prostacyclin: an Inflammatory Paradox
    REVIEW ARTICLE published: 13 May 2011 doi: 10.3389/fphar.2011.00024 Prostacyclin: an inflammatory paradox Jeremiah Stitham, Charles Midgett, Kathleen A. Martin and John Hwa* Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA Edited by: Prostacyclin (PGI2) is a member of the prostaglandin family of bioactive lipids. Its best- Angel Lanas, University of Zaragoza, characterized role is in the cardiovascular system, where it is released by vascular endothelial cells, Spain serving as a potent vasodilator and inhibitor of platelet aggregation. In recent years, prostacyclin Reviewed by: Emer Smyth, University of (PGI2) has also been shown to promote differentiation and inhibit proliferation in vascular smooth Pennsylvania, USA muscle cells. In addition to these well-described homeostatic roles within the cardiovascular Steven W. Kerrigan, Royal College of system, prostacyclin (PGI2) also plays an important role as an inflammatory mediator. In this Surgeons in Ireland, Ireland review, we focus on the contribution of prostacyclin (PGI2) as both a pathophysiological mediator *Correspondence: and therapeutic agent in three major inflammatory-mediated disease processes, namely John Hwa, Section of Cardiovascular Medicine, Department of Internal rheumatoid arthritis, where it promotes disease progression (“pro-inflammatory”), along Medicine, Yale School of Medicine, with pulmonary vascular disease and atherosclerosis, where it inhibits disease progression Cardiovascular Research Center, 300 (“anti-inflammatory”). The emerging role of prostacyclin (PGI2) in this context provides new George Street, Room 759H, New opportunities for understanding the complex molecular basis for inflammatory-related diseases, Haven, CT 06511, USA. e-mail: [email protected] and insights into the development of current and future anti-inflammatory treatments.
    [Show full text]
  • Effect of Non-Steroidal Anti-Inflammatory Ophthalmic Solution on Intraocular Pressure Reduction by Latanoprost K Kashiwagi, S Tsukahara
    297 CLINICAL SCIENCE Br J Ophthalmol: first published as 10.1136/bjo.87.3.297 on 1 March 2003. Downloaded from Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost K Kashiwagi, S Tsukahara ............................................................................................................................. Br J Ophthalmol 2003;87:297–301 Aim: To investigate the effects of a non-steroidal anti-inflammatory drug (NSAID) ophthalmic solution on latanoprost induced intraocular pressure (IOP) reduction using normal volunteers. Methods: This study was conducted as a prospective and observer masked clinical trial. 13 normal volunteers were enrolled. After measurement of basal IOP and ophthalmic examination, latanoprost ophthalmic solution was initially administered to both eyes once daily. Four weeks later, an NSAID ophthalmic solution, sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate (refer to bromfenac sodium hydrate), was co-administered to one randomly selected eye (NSAID group) twice daily for 2 weeks. The other eye was employed as a control (non-NSAID group). After withdrawal of the NSAID ophthalmic solution, latanoprost ophthalmic solution was continuously administered for another 2 weeks and was then withdrawn. After a 4 week washout, only bromfenac sodium hydrate See end of article for authors’ affiliations ophthalmic solution was administered to the eyes of the NSAID group for 2 weeks. During the study ....................... period, ophthalmic examination, including IOP measurement was performed in an observer masked fashion. Correspondence to: Results: Kenji Kashiwagi, MD, Before initiation of bromfenac sodium hydrate, baseline IOPs of the non-NSAID group and the Department of NSAID group were 15.73 (SD 1.97) mm Hg and 15.86 (2.06) mm Hg, respectively (p=0.88).
    [Show full text]
  • Curriculum Vitae FA Fitzpatrick
    Curriculum Vitae F.A. Fitzpatrick Business email: [email protected] Business phone:816-654-7637 F. A. Fitzpatrick - Curriculum Vitae 2 Frank A. Fitzpatrick EDUCATION B.S. Chemistry, Villanova University, 1969 Ph.D. Analytical Chemistry, University of Massachusetts at Amherst, 1972 PROFESSIONAL EXPERIENCE Kansas City University of Medicine and Biosciences, Kansas City, MO 2009 – now Professor, Division of Biomedical Sciences, Pharmacology & Microbiology 2012 – 2015 Director, Second Year Curriculum, College of Medicine The Huntsman Cancer Institute / University of Utah School of Medicine, Salt Lake City, Utah 1997 – 2009 Professor, Department of Oncological Science and Department of Medicinal Chemistry 1999 – 2001 Senior Director of Research & Development 2001 – 2004 Senior Director for Translational Research The University of Colorado School of Medicine Denver, Colorado 1992 - 1994 Professor, Department of Pharmacology 1987 - 1992 Associate Professor, Department of Pharmacology Pharmacia & Upjohn Company (formerly The Upjohn Company) Kalamazoo, Michigan 1996 - 1997 Vice President, Discovery Research 1994 - 1996 Director, Cell Biology & Inflammation Research 1987 Director, Chemical and Biological Screening 1982-1987 Lipids Research Distinguished Research Scientist IV of V 1974-1982 Drug Metabolism Research Scientist I, 1974-75 Scientist II, 1975-80 Senior Scientist III, 1980-83 Karolinska Institute Stockholm, Sweden 1982-1983 Visiting Research Scientist Department of Physiological Chemistry Professor Bengt Samuelsson, M.D., Nobel Laureate
    [Show full text]